Mold, water-damaged buildings and VOCs: why buildings keep appearing in MCS onset and relapse stories

Water-damaged buildings, renovation, new construction, and indoor VOC mixtures repeatedly appear in MCS onset and relapse histories. That makes buildings an important exposure context. It does not justify reducing every case to “mold toxicity” or assuming one indoor contaminant explains a multisystem disorder.

Buildings can contain complex mixtures of moisture-related contaminants, fragrances, solvents, cleaning chemicals, combustion products, and new-material emissions. MCS research repeatedly points to buildings as important exposure settings — but that does not mean one organism or one toxin explains every case.

This site’s practical mold pages — Mold, CIRS & chemical sensitivity, the biotoxin science and testing and remediation — cover what to do. This page covers what the evidence shows.

What we know

For many people with MCS, a building is not merely the place where symptoms happen. The building is part of the onset story. New carpet, paint, adhesives, remodeling, cleaning products, fragrances, dampness, mold growth, gas appliances, and mixtures of volatile organic compounds have all appeared in patient histories and research cohorts.

The scientific challenge is that "the building" is not one exposure. A water-damaged building can contain microbial material, dampness-related by-products, cleaning chemicals, fragrances, building-material emissions, particles, and ordinary VOCs at the same time. A newly remodeled building has a different mixture. Treating every building-related case as "mold toxicity" is therefore just as simplistic as treating every case as anxiety about odors.

What the evidence shows

One classic study compared 112 people who attributed the onset of chemical sensitivity either to cholinesterase-inhibiting pesticide exposure or to building remodeling. Despite very different initiating settings, the two groups later reported similar patterns of symptoms and similar inhalant and ingestant triggers. The pesticide group reported greater severity in several symptom domains, but the similarity of the later intolerance pattern suggested a possible final common pathway.

A separate case report followed four chemically sensitive women after relocation to a newly constructed office building. Three reported substantial worsening and spreading of sensitivities after occupancy. Indoor total VOC levels were relatively low by conventional standards and changed over time. The small case series cannot establish causation, but it illustrates why a simple "below the toxic limit, therefore irrelevant" framework may miss susceptibility.

More recent intervention data are especially useful because they measured the environment rather than relying only on memory. In a 2022 environmental-house-call study, participants with chemical intolerance had indoor VOCs measured before and after individualized exposure-reduction recommendations. Homes that achieved the largest VOC reductions generally showed the greatest symptom improvement; symptom improvement generally was not reported in homes without VOC improvement. A 2024 follow-up described three cases from the larger program in more detail.

These studies support taking the indoor environment seriously. They still do not prove that any one VOC, mold species, mycotoxin, fragrance ingredient, or other building contaminant is the universal cause of MCS. The intervention was not a randomized blinded trial, and chemical intolerance is broader than a rigorously confirmed consensus-defined MCS cohort.

Mold deserves the same discipline. Water-damaged buildings are commonly reported in chemical-intolerance onset histories, and damp buildings are clearly associated with respiratory illness in the broader environmental-health literature. But the leap from "MCS began in a moldy building" to "MCS is caused by mold toxin accumulation" is not established. The exposure mixture and host susceptibility have to be disentangled.

What the registry is answering

The registry should capture building exposure in detail rather than using a single checkbox for "mold." Questions should separate visible dampness, documented mold, new construction, renovation, carpet/flooring, paint, adhesives, fragrances, cleaning chemicals, combustion sources, gas appliances, workplace changes, and measured air-quality data where available.

Chronology matters again. Did symptoms begin before the person knew the building had a problem? Did they improve after leaving? Did they recur on return? Were coworkers or family members affected? Are there inspection records, VOC measurements, moisture reports, or medical records from before the environmental explanation was formed?

That structure turns "I got sick in a building" into a testable exposure history.

Where we stand

Buildings are a legitimate and important part of the MCS evidence base. Remodeling, indoor VOCs, fragranced products, combustion sources, and water-damaged environments repeatedly appear as initiators or triggers, and measured reductions in indoor VOCs have tracked with symptom improvement in intervention work.

We do not reduce that evidence to "mold causes MCS" or "the building poisoned everyone." Our position is broader: complex indoor environments can matter greatly to susceptible people, and the specific initiating agents and biological pathways need to be measured rather than assumed.

We followed the evidence. Here’s where it leads →

Sources

1Miller CS, Mitzel HC. Chemical sensitivity attributed to pesticide exposure versus remodeling. Arch Environ Health 1995;50(2):119-29. PMID: 7786048. DOI: 10.1080/00039896.1995.9940889
2Miller CS, Gammage RB, Jankovic JT. Exacerbation of chemical sensitivity: a case study. Toxicol Ind Health 1999;15(3-4):398-402. PMID: 10416291. DOI: 10.1177/074823379901500313
3Perales RB et al. Does improving indoor air quality lessen symptoms associated with chemical intolerance?. Prim Health Care Res Dev 2022;23:e3. PMID: 35019834. DOI: 10.1017/S1463423621000864
4Rincón R et al. Environmental house calls can reduce symptoms of chemical intolerance: a demonstration of personalized exposure medicine. Prim Health Care Res Dev 2024;25:e53. PMID: 39434594. DOI: 10.1017/S146342362400046X
← Back to MCSDisability.com
↑